Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2020

08.05.2020 | Epidemiology

The impact of ductal carcinoma in situ on health services utilization

verfasst von: Lawrence Paszat, Rinku Sutradhar, Eileen Rakovitch

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To determine the intermediate-term impact of diagnosis and treatment of ductal carcinoma in situ of the breast (DCIS) on health services utilization, we compared utilization by cases of DCIS to unaffected controls.

Methods

We identified a population-based cohort of Ontario females diagnosed with DCIS between 2010 and 2015. We matched 5 controls without any history of cancer to each case, on the date of diagnosis of the case (the index date), by age, annual mammography history, socioeconomic status, and comorbidity. We identified billing claims and hospital records, during the interval 13 to 60 months prior to, and subsequent to the index date, and computed rates per 100 person-years during both intervals, to conduct a difference-in-differences analysis. We used negative binomial regression to test if the change in rates in health services differed between cases and controls.

Results

Visits with a breast diagnosis code, and claims for breast surgery and imaging, were significantly increased among cases compared to controls (all p values < 0.0001) after DCIS;however, there was no increase in visits for anxiety or depression (RR 1.13 (95% CI 0.97, 1.32, p = 0.11), visits to psychiatrists (RR 1.07 (95% CI 0.82, 1.40) p = 0.6), or hospital procedures other than breast surgery (RR 1.10 (95% CI 0.88, 1.37) p = 0.4).

Conclusions

DCIS is associated with more visits and procedures related to the breast compared to controls following diagnosis and treatment, but other health services utilization and visits related to anxiety and depression were not increased.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Wapnir IL, Dignam JJ, Fisher B et al (2011 ) Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103(6):478–488CrossRef Wapnir IL, Dignam JJ, Fisher B et al (2011 ) Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103(6):478–488CrossRef
2.
Zurück zum Zitat Cuzick J, Sestak I, Pinder SE et al (2011) Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 12(1):21–29CrossRef Cuzick J, Sestak I, Pinder SE et al (2011) Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 12(1):21–29CrossRef
3.
Zurück zum Zitat Donker M, Litière S, Werutsky G et al (2013 ) Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol 31(32):4054–4059CrossRef Donker M, Litière S, Werutsky G et al (2013 ) Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol 31(32):4054–4059CrossRef
4.
Zurück zum Zitat Wärnberg F, Garmo H, Emdin S et al (2014 ) Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial. J Clin Oncol 32(32):3613–3618CrossRef Wärnberg F, Garmo H, Emdin S et al (2014 ) Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial. J Clin Oncol 32(32):3613–3618CrossRef
5.
Zurück zum Zitat McCormick B, Winter K, Hudis C et al (2015 ) RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol 33(7):709–715CrossRef McCormick B, Winter K, Hudis C et al (2015 ) RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol 33(7):709–715CrossRef
7.
Zurück zum Zitat EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C et al (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383(9935):2127–2135CrossRef EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C et al (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383(9935):2127–2135CrossRef
8.
Zurück zum Zitat Gøtzsche PC (2004 ) Re: Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 96(16):1257CrossRef Gøtzsche PC (2004 ) Re: Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 96(16):1257CrossRef
9.
Zurück zum Zitat Jones JL (2006) Overdiagnosis and overtreatment of breast cancer: progression of ductal carcinoma in situ: the pathological perspective. Breast Cancer Res 8(2):204CrossRef Jones JL (2006) Overdiagnosis and overtreatment of breast cancer: progression of ductal carcinoma in situ: the pathological perspective. Breast Cancer Res 8(2):204CrossRef
10.
Zurück zum Zitat Kumar AS, Bhatia V, Henderson IC (2005) Overdiagnosis and overtreatment of breast cancer: rates of ductal carcinoma in situ: a US perspective. Breast Cancer Res 7(6):271–275CrossRef Kumar AS, Bhatia V, Henderson IC (2005) Overdiagnosis and overtreatment of breast cancer: rates of ductal carcinoma in situ: a US perspective. Breast Cancer Res 7(6):271–275CrossRef
11.
Zurück zum Zitat Hosseini A, Khoury AL, Esserman LJ (2017 ) Precision surgery and avoiding over-treatment. Eur J Surg Oncol 43(5):938–943CrossRef Hosseini A, Khoury AL, Esserman LJ (2017 ) Precision surgery and avoiding over-treatment. Eur J Surg Oncol 43(5):938–943CrossRef
13.
Zurück zum Zitat Elshof LE, Tryfonidis K, Slaets L et al (2015) Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study. Eur J Cancer 51(12):1497–1510. https://doi.org/10.1016/j.ejca.2015.05.008 CrossRef Elshof LE, Tryfonidis K, Slaets L et al (2015) Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study. Eur J Cancer 51(12):1497–1510. https://​doi.​org/​10.​1016/​j.​ejca.​2015.​05.​008 CrossRef
15.
Zurück zum Zitat Solin LJ, Gray R, Baehner FL et al (2013 ) A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 105(10):701–710CrossRef Solin LJ, Gray R, Baehner FL et al (2013 ) A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 105(10):701–710CrossRef
17.
Zurück zum Zitat Rakovitch E, Nofech-Mozes S, Hanna W et al (2015 ) A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat 152(2):389–398CrossRef Rakovitch E, Nofech-Mozes S, Hanna W et al (2015 ) A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat 152(2):389–398CrossRef
19.
Zurück zum Zitat Rakovitch E, Franssen E, Kim J, Ackerman I, Pignol JP, Paszat L, Pritchard KI, Ho C, Redelmeier DA (2003 ) A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat 77(3):285–293CrossRef Rakovitch E, Franssen E, Kim J, Ackerman I, Pignol JP, Paszat L, Pritchard KI, Ho C, Redelmeier DA (2003 ) A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat 77(3):285–293CrossRef
20.
Zurück zum Zitat van Gestel YR, Voogd AC, Vingerhoets AJ, Mols F, Nieuwenhuijzen GA, van Driel OJ, van Berlo CL, van de Poll-Franse LV (2007 ) A comparison of quality of life, disease impact and risk perception in women with invasive breast cancer and ductal carcinoma in situ. Eur J Cancer 43(3):549–556CrossRef van Gestel YR, Voogd AC, Vingerhoets AJ, Mols F, Nieuwenhuijzen GA, van Driel OJ, van Berlo CL, van de Poll-Franse LV (2007 ) A comparison of quality of life, disease impact and risk perception in women with invasive breast cancer and ductal carcinoma in situ. Eur J Cancer 43(3):549–556CrossRef
21.
Zurück zum Zitat Lauzier S, Maunsell E, Levesque P, Mondor M, Robert J, Robidoux A, Provencher L (2010 ) Psychological distress and physical health in the year after diagnosis of DCIS or invasive breast cancer. Breast Cancer Res Treat 120(3):685–691CrossRef Lauzier S, Maunsell E, Levesque P, Mondor M, Robert J, Robidoux A, Provencher L (2010 ) Psychological distress and physical health in the year after diagnosis of DCIS or invasive breast cancer. Breast Cancer Res Treat 120(3):685–691CrossRef
22.
Zurück zum Zitat Liu Y, Pérez M, Schootman M, Aft RL, Gillanders WE, Jeffe DB (2011 ) Correlates of fear of cancer recurrence in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat 130(1):165–173CrossRef Liu Y, Pérez M, Schootman M, Aft RL, Gillanders WE, Jeffe DB (2011 ) Correlates of fear of cancer recurrence in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat 130(1):165–173CrossRef
23.
Zurück zum Zitat Gregorowitsch ML, van den Bongard HJGD, Young-Afat DA, Pignol JP, van Gils CH, May AM, Verkooijen HM (2018 ) Severe depression more common in patients with ductal carcinoma in situ than early-stage invasive breast cancer patients. Breast Cancer Res Treat 167(1):205–213CrossRef Gregorowitsch ML, van den Bongard HJGD, Young-Afat DA, Pignol JP, van Gils CH, May AM, Verkooijen HM (2018 ) Severe depression more common in patients with ductal carcinoma in situ than early-stage invasive breast cancer patients. Breast Cancer Res Treat 167(1):205–213CrossRef
24.
Zurück zum Zitat Partridge A, Adloff K, Blood E, Dees EC, Kaelin C, Golshan M, Ligibel J, de Moor JS, Weeks J, Emmons K, Winer E (2008 ) Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst 100(4):243–251. https://doi.org/10.1093/jnci/djn010 CrossRef Partridge A, Adloff K, Blood E, Dees EC, Kaelin C, Golshan M, Ligibel J, de Moor JS, Weeks J, Emmons K, Winer E (2008 ) Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst 100(4):243–251. https://​doi.​org/​10.​1093/​jnci/​djn010 CrossRef
26.
Zurück zum Zitat Yang H, Brand JS, Fang F, Chiesa F, Johansson AL, Hall P, Czene K (2017) Time-dependent risk of depression, anxiety, and stress-related disorders in patients with invasive and in situ breast cancer. Int J Cancer 140(4):841–852CrossRef Yang H, Brand JS, Fang F, Chiesa F, Johansson AL, Hall P, Czene K (2017) Time-dependent risk of depression, anxiety, and stress-related disorders in patients with invasive and in situ breast cancer. Int J Cancer 140(4):841–852CrossRef
27.
Zurück zum Zitat Hanchate AD, Kapoor A, Katz JN et al (2015) Massachusetts health reform and disparities in joint replacement use: difference in differences study. BMJ 350:h440CrossRef Hanchate AD, Kapoor A, Katz JN et al (2015) Massachusetts health reform and disparities in joint replacement use: difference in differences study. BMJ 350:h440CrossRef
28.
Zurück zum Zitat Introduction to econometrics, James H. Stock, Mark W. Watson. 2nd ed., Boston: Pearson Addison Wesley, 2007. Introduction to econometrics, James H. Stock, Mark W. Watson. 2nd ed., Boston: Pearson Addison Wesley, 2007.
29.
Zurück zum Zitat Trentham-Dietz A, Newcomb PA, Storer BE, Remington PL (2000 ) Risk factors for carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 9(7):697–703 Trentham-Dietz A, Newcomb PA, Storer BE, Remington PL (2000 ) Risk factors for carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 9(7):697–703
30.
Zurück zum Zitat Claus EB, Stowe M, Carter D (2003) Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. Breast Cancer Res Treat 78(1):7–15CrossRef Claus EB, Stowe M, Carter D (2003) Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. Breast Cancer Res Treat 78(1):7–15CrossRef
32.
Zurück zum Zitat Gill JK, Maskarinec G, Pagano I, Kolonel LN (2006) The association of mammographic density with ductal carcinoma in situ of the breast: the Multiethnic Cohort. Breast Cancer Res 8(3):R30CrossRef Gill JK, Maskarinec G, Pagano I, Kolonel LN (2006) The association of mammographic density with ductal carcinoma in situ of the breast: the Multiethnic Cohort. Breast Cancer Res 8(3):R30CrossRef
33.
Zurück zum Zitat MacKenzie TA, Titus-Ernstoff L, Vacek PM, Geller B, Weiss JE, Goodrich ME, Carney PA (2007 ) Breast density in relation to risk of ductal carcinoma in situ of the breast in women undergoing screening mammography. Cancer Causes Control 18(9):939–945CrossRef MacKenzie TA, Titus-Ernstoff L, Vacek PM, Geller B, Weiss JE, Goodrich ME, Carney PA (2007 ) Breast density in relation to risk of ductal carcinoma in situ of the breast in women undergoing screening mammography. Cancer Causes Control 18(9):939–945CrossRef
34.
Zurück zum Zitat Longnecker MP, Bernstein L, Paganini-Hill A, Enger SM, Ross RK (1996 ) Risk factors for in situ breast cancer. Cancer Epidemiol Biomarkers Prev 5(12):961–965 Longnecker MP, Bernstein L, Paganini-Hill A, Enger SM, Ross RK (1996 ) Risk factors for in situ breast cancer. Cancer Epidemiol Biomarkers Prev 5(12):961–965
35.
Zurück zum Zitat Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, Buist DS, Barlow WE, Cutter G, Geller BM, Yankaskas B, Taplin SH, Carney PA (2003 ) Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol 21(23):4314–4321CrossRef Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, Buist DS, Barlow WE, Cutter G, Geller BM, Yankaskas B, Taplin SH, Carney PA (2003 ) Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol 21(23):4314–4321CrossRef
38.
Zurück zum Zitat Kerlikowske K, Barclsay J, Grady D, Sickles EA, Ernster V (1997 ) Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. J Natl Cancer Inst 89(1):76–82CrossRef Kerlikowske K, Barclsay J, Grady D, Sickles EA, Ernster V (1997 ) Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. J Natl Cancer Inst 89(1):76–82CrossRef
Metadaten
Titel
The impact of ductal carcinoma in situ on health services utilization
verfasst von
Lawrence Paszat
Rinku Sutradhar
Eileen Rakovitch
Publikationsdatum
08.05.2020
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2020
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05664-9

Weitere Artikel der Ausgabe 1/2020

Breast Cancer Research and Treatment 1/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.